CombiPlex is an approach using drug carriers (nano-scale liposomes) to deliver synergistic ratios of drug combinations for the treatment of cancer.
Celator Pharma claims that in contrast to conventional combination drug regimens, which do not take this potential into account, CombiPlex identifies a synergistic ratio of the drugs and locks that combination in nano-scale (about 100 times smaller than a red blood cell) carriers that are able to deliver and maintain the synergistic drug ratio after injection into patients.
The extended delivery of a synergistic ratio of drugs is intended to increase the effectiveness of the combination and improve clinical outcomes.
Celator Pharma CEO Scott Jackson said that they are pleased to receive this patent which broadly protects Celator’s CombiPlex technology, the foundation of the current product pipeline.
"Our lead investigational product, CPX-351, recently reported positive Phase 2 data and planning is underway for Phase 3," Jackson said.
"With the Patent Term Adjustment, this patent provides protection until January 2027, which significantly extends market exclusivity for CPX-351."